Remco A. Spanjaard

Prof. Remco A. Spanjaard

Boston University School of Medicine, USA



1989 Ph.D., University of Leiden, Gene regulation

1984 M.Sc., University of Leiden, Cell Biology

1982 B.Sc., University of Leiden, Biology/Chemistry

Publications (selected)

  1. Demary K, Wong L, Liou JS, Faller DV, Spanjaard RA. Redox-control of retinoic acid (RA) receptor activity: a novel mechanism for RA-resistance in melanoma cells. Endocrinology 2001; 142:2600-2605.
  2. Krishna S, Brown N, Faller DV, Spanjaard RA. Differential effects of short chain fatty acids on head and neck squamous carcinoma cells. Laryngoscope 2002; 112:645-650.
  3. Hoa M, Davis SL, Ames SJ, Spanjaard RA. Amplification of wild-type K-RAS promotes growth of head and neck squamous cell carcinoma. Cancer Res 2002; 62:7154-7156.
  4. Chen JS, Faller DV, Spanjaard RA. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets 2003; 3:219-236.
  5. Zhao X, Patton JR, Davis SL, Florence B, Ames SJ, Spanjaard RA. Regulation of nuclear receptor activity by a pseudouridine synthase through posttranscriptional modification of Steroid Receptor RNA Activator. Mol Cell 2004; 15:549-558.
  6. Zhao X, Ayer RE, Davis SL, Ames SJ, Florence B, Torchinsky C, Liou JS, Shen L, Spanjaard RA. Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. Cancer Res 2005; 65:2125-2129.
  7. Mork C, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 2005; 11:1091-1104.
  8. Gu J, Zhao X, Spanjaard RA, Chen TC, Flannagan JN, Boosalis M, Perrine SP, Faller DV. Histone deacetylase-inhibitors sensitize human prostate cancer cell lines to growth suppression and apoptosis by retinoids. J Cancer Molecules 2006; 2:25-36.
  9. Abujamra AL, Spanjaard RA, Akinsheye I, Zhao X, Faller DV, Ghosh SK. Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism. Virology 2006; 345:390-403.
  10. Zhao X, Patton JR, Ghosh SK, Fischel-Ghodsian N, Shen L, Spanjaard RA.Pus3p and Pus1p-dependent pseudouridylation of steroid receptor RNA activator controls a functional switch that regulates nuclear receptor signaling. Mol Endocrinol 2007;21:686-699.
  11. Spanjaard RA, Whren KM, Graves C, Bhawan J. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. Int J Cancer 2007;120:1304-1310
  12. Mork CN, Faller DV, Spanjaard RA. Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett 2007;581:5440-5444.
  13. Rankin AM, Faller DV, Spanjaard RA. Telomerase inhibitors and ‘T-oligo’ as cancertherapeutics:contrasting molecular mechanisms of cytotoxicity. AntiCancer Drugs 2008; 19:329-338.
  14. Zhao X, Graves C, Ames SJ, Spanjaard RA. Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-γ target gene CHST10. Cancer Res 2009;69:5218-5225.
  15. Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 2009;29:3547-3553.